Source

Gastroenterology Unit, University of Naples "Federico II", Naples, Italy.

Abstract

BackgroundIn vitro, vitamin B(12) acts as a natural inhibitor of hepatitis C virus (HCV) replication.ObjectiveTo assess the effect of vitamin B(12) on virological response in patients with chronic HCV hepatitis naïve to antiviral therapy.MethodsNinety-four patients with chronic HCV hepatitis were randomly assigned to receive pegylated interferon α plus ribavirin (standard-of-care; SOC) or SOC plus vitamin B(12) (SOC+B(12)). Viral response-namely, undetectable serum HCV-RNA, was evaluated 4 weeks after starting treatment (rapid viral response), 12 weeks after starting treatment (complete early viral response) and 24 or 48 weeks after starting treatment (end-of-treatment viral response) and 24 weeks after completing treatment (sustained viral response (SVR)). Genotyping for the interleukin (IL)-28B polymorphism was performed a posteriori in a subset (42/64) of HCV genotype 1 carriers.ResultsOverall, rapid viral response did not differ between the two groups, whereas the rates of complete early viral response (p=0.03), end-of-treatment viral response (p=0.03) and SVR (p=0.001) were significantly higher in SOC+B(12) patients than in SOC patients. In SOC+B(12) patients, the SVR rate was also significantly higher in carriers of a difficult-to-treat genotype (p=0.002) and in patients with a high baseline viral load (p=0.002). Distribution of genotype IL-28B did not differ between the two groups. At multivariate analysis, only easy-to-treat HCV genotypes (OR=9.00; 95% CI 2.5 to 37.5; p=0.001) and vitamin B(12) supplementation (OR=6.9; 95% CI 2.0 to 23.6; p=0.002) were independently associated with SVR.ConclusionVitamin B(12) supplementation significantly improves SVR rates in HCV-infected patients naïve to antiviral therapy.